Ozempic vs Mounjaro vs Wegovy: An Honest Comparison

The GLP-1 category now includes four drugs in mainstream use, with several more in trials. The brand-name confusion is real — and the differences between them matter for clinical decisions.

Quick orientation:

• Ozempic (semaglutide) — branded for type-2 diabetes
• Wegovy (semaglutide) — same molecule, branded for weight management at higher doses
• Mounjaro (tirzepatide) — branded for type-2 diabetes
• Zepbound (tirzepatide) — same molecule, branded for weight management

So Ozempic and Wegovy are the same drug at different dose ranges. Mounjaro and Zepbound are the same drug at different dose ranges. The actual choice you face is semaglutide (Ozempic/Wegovy) vs tirzepatide (Mounjaro/Zepbound).

Mechanism: GLP-1 alone vs dual GLP-1/GIP

Semaglutide is a single-target drug. It mimics GLP-1, a gut hormone that suppresses appetite via central pathways, slows gastric emptying, and stimulates glucose-dependent insulin secretion.

Tirzepatide is a dual agonist. It mimics GLP-1 AND GIP (glucose-dependent insulinotropic polypeptide), a second incretin hormone with overlapping but distinct effects on insulin secretion and energy expenditure.

The dual mechanism is why tirzepatide is more effective for weight loss than semaglutide on average. The exact reason GIP agonism amplifies the effect is still being characterized, but the trial outcomes are clear.

Effectiveness — head-to-head data

The pivotal trials don't directly compare the two drugs in the same protocol, but the headline numbers from each are:

Semaglutide (STEP 1): 14.9% mean body-weight reduction at 68 weeks at the highest dose (2.4 mg).

Tirzepatide (SURMOUNT-1): 20.9% mean body-weight reduction at 72 weeks at the highest dose (15 mg).

STEP 5 (semaglutide 2-year): 15.2% sustained at 104 weeks. Maintenance is real on the drug.

The SURMOUNT-2 trial (tirzepatide in T2D) found 15.7% weight loss; STEP 2 (semaglutide in T2D) showed 9.6%. So tirzepatide is more effective in diabetic populations as well.

Practical translation: at the highest doses, tirzepatide produces ~5–6% more weight loss than semaglutide. For someone starting at 100 kg, that's ~5–6 kg additional. Meaningful difference.

Cardiovascular benefit

This is where semaglutide currently has the strongest data:

SELECT trial (semaglutide): 20% reduction in major adverse cardiovascular events in obese non-diabetic adults with prior CV disease. This is the most robust CV outcomes data in the category.

Tirzepatide CV trials: SURMOUNT-MMO is the major outcomes trial; primary results are more recent and not yet as widely cited as SELECT. Early data suggests CV benefit, but the strength of the case is currently behind semaglutide.

Practical translation: if cardiovascular benefit is your primary indication (existing CVD, family history, prior cardiac event), semaglutide currently has the better evidence base. If pure weight loss is the goal, tirzepatide is more effective.

Side-effect profiles

Both drugs have similar GI-side-effect categories — nausea, diarrhea, vomiting, constipation. Most resolve within 4–8 weeks of starting or escalating doses.

Semaglutide-specific patterns:

• More frequent nausea reports at full dose (2.4 mg)
• Slightly more constipation reports
• Reflux and slow gastric emptying issues common

Tirzepatide-specific patterns:

• Fewer nausea reports at equivalent weight-loss-effective doses (the GIP agonism may modestly reduce GI side effects)
• More diarrhea reports, especially during dose escalation
• Some reports of more dramatic appetite suppression — both a benefit and a risk for under-eating

The Linge 2024 lean-mass-loss data applies similarly to both drugs. Both produce 25–40% lean-mass loss without active countermeasures.

Cost and access

In the US, list prices are similar (~$1,000–1,500/mo without insurance for both). Insurance coverage varies wildly by plan and indication.

Semaglutide (Ozempic) for diabetes: typically well-covered by insurance.

Semaglutide (Wegovy) for weight management: coverage is improving but still inconsistent. Some employers added coverage in 2024–2025; many haven't.

Tirzepatide (Mounjaro) for diabetes: typically covered for diabetic patients, similar to Ozempic.

Tirzepatide (Zepbound) for weight management: coverage similar to Wegovy — improving but still inconsistent.

Compounded versions: various pharmacies sell compounded semaglutide and tirzepatide. The FDA has issued warnings about quality variability in compounded products. We don't recommend them — the difference between branded and compounded is not just price; it's quality control. If cost is the issue, the patient-assistance programs from the manufacturers (Novo Nordisk for semaglutide, Lilly for tirzepatide) are worth investigating before turning to compounding pharmacies.

Generic timeline: semaglutide patents extend into 2031; tirzepatide further. Generic versions (which would substantially reduce cost) are years away.

How to choose

Pick semaglutide (Ozempic/Wegovy) if:

• You have established cardiovascular disease and CV risk reduction is the priority (SELECT-trial-grade evidence)
• You have severe nausea sensitivity and want the more-studied side-effect profile
• Insurance coverage favors it
• You're starting at lower BMI (30–35) where 15% weight loss is sufficient

Pick tirzepatide (Mounjaro/Zepbound) if:

• Weight loss is the primary goal and you want maximum effect (20%+ vs 15%)
• You have BMI ≥40 where larger weight loss matters more clinically
• You've tried semaglutide and the response was insufficient
• Cost and insurance coverage favor it

For type-2 diabetes specifically: both are effective. Tirzepatide tends to produce slightly better glycemic control alongside the larger weight loss. Many endocrinologists now prefer tirzepatide as first-line for diabetic obese patients.

Switching between drugs

It's reasonable to switch if the first drug isn't producing adequate response after 6 months at the maximum tolerated dose. The transition typically involves:

• Stopping the first drug
• 2–4 week washout
• Starting the second drug at the lowest dose, escalating per protocol

There's no medical reason to alternate between them on a regular schedule. Pick one, give it a fair trial (12+ months at a stable maximum dose), and switch only if the response is inadequate.

Marketing noise to ignore

A few things you'll see in the cultural conversation that don't matter clinically:

"Compounded is just as good." No. Compounded products lack the quality control of branded production. The cost savings come with real risks.

"Microdosing" GLP-1s. The trial data is at full doses. Microdosing isn't well-studied; the cardiovascular benefits in particular were established at full dose. Don't make up your own dosing protocol.

"Natural alternatives" claiming GLP-1-like effects. Berberine, fenugreek, etc. None come close to the trial-grade weight loss of actual GLP-1s. They may have modest metabolic benefits but are categorically different interventions.

"Stack" with other weight-loss drugs. Combining GLP-1 with phentermine, naltrexone-bupropion, or other weight-loss drugs is being marketed by some clinics. Limited data; do this only with a careful prescriber who can monitor for interactions.

Long-term considerations

Both drugs are intended for chronic use. The trial data on year 2+ outcomes is now reasonable — STEP 5 showed 15.2% weight loss sustained at 104 weeks; SURMOUNT-MMO is generating year 3+ data.

Long-term safety questions still being characterized:

• Pancreatitis risk (rare but documented)
• Thyroid C-cell tumor risk in animal models (humans appear safe but monitoring continues)
• Gastroparesis risk (slow stomach emptying becoming a chronic issue for some users)
• Vision changes (small number of reports of NAION-related concerns)
• Mental health effects (some users report mood changes; under active study)

For both drugs, the 5–10 year safety data isn't fully developed yet. That's worth weighing.

The summary

For most adults choosing between the two drugs:

• Tirzepatide is more effective for weight loss (20%+ vs 15%)
• Semaglutide has the stronger cardiovascular outcomes data currently
• Side-effect profiles are similar with minor differences
• Costs are comparable — insurance coverage drives the practical access difference
• Picking one and committing beats switching back and forth

If you're uncertain, talk to your prescriber about which they have more clinical experience with — the practical management of side effects and dose-escalation matters as much as the molecule difference.

For the protocol that goes around either drug — the protein, strength, sleep, UPF reduction work — see Preventing Muscle Loss on Ozempic. The drug choice matters; the protocol around it matters more.